Dr. Peter G. Stock, MD

Dr. Stock practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Stock's NPI, 1801850805, was assigned on April 14, 2006. Dr. Stock graduated from University of Illinois College of Medicine at Chicago in 1982. Dr. Stock holds California license G68680.

Dr. Stock's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Stock's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Stock to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stock practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Stock's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Stock is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Stock's licenses on file in 3 states: California, Hawaii and Minnesota.

Dmand AI lists intestinal or bowel obstruction and kidney transplant among the conditions Dr. Stock treats.

CMS data shows 104 Medicare services from Dr. Stock across 4 procedure codes in 2024, for 65 Medicare patients. Medicare paid $9,544 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 65 Medicare patients who saw Dr. Stock in 2024. The largest group is under 65, with 38 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 66% are also on Medicaid. Their average risk score is 6.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stock's median patient age at 48, with 42% women.

In 2024, Dr. Stock wrote 96 Medicare Part D claims. 76% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $74 in total drug cost. In 2023, CMS named 17 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Stock for performance year 2024, reported as part of a group. Dr. Stock accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stock as offering telehealth.

Dmand AI links 235 papers to Dr. Stock, published from 2008 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Graft Survival, Kidney Transplantation and Graft Rejection. Dr. Stock has published most often in Am J Transplant. Dr. Stock's most frequent co-authors are Nancy L. Ascher, MD, Chris E. Freise, MD and Andrew M. Posselt, MD.

Dmand AI links Dr. Stock to 7 clinical trials, 2 of them phase 2 studies. Conditions studied include HIV Infections, Lentivirus Infections and Acquired Immunodeficiency Syndrome. University of California, San Francisco sponsors the most, 4.

CMS Open Payments shows 16 general payments to Dr. Stock from 4 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 70% of the total. Astellas Pharma Inc paid the most, $24,166.

Dmand AI lists 4 awards for Dr. Stock, most recently Regional Top Doctor in 2014.

Dr. Stock graduated from University of Illinois College of Medicine at Chicago in 1982. Dr. Stock is a member of ACS.

Dr. Stock is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.